Compare DexCom, Inc. (DXCM) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Redwire Corporation — how do they compare? DexCom, Inc. trades at $89.18 (market cap $33.79B), while Redwire Corporation trades at $13.39 (market cap $3.38B). The key difference: DexCom, Inc. is far larger — about 10× Redwire Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| DXCM | RDW | |
|---|---|---|
Market Cap | $33.79B | $3.38B |
Sector | Health | Technology |
52-Week High | $89.53 | $25.90 |
52-Week Low | $54.84 | $5.06 |
Enterprise Value | $33.24B | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Redwire (RDW) trades at $13.65, up 4.04% today, with strong technical momentum as moving averages signal bullish sentiment. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant net losses. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $17.50 price target, representing 28% upside potential from current levels.
While Redwire shows impressive revenue growth and defense contract momentum, investors face substantial risk from persistent losses, negative cash flow from operations, and high valuation multiples despite unprofitability. The company's pivot toward defense technology provides near-term stability but requires careful monitoring of margin improvement and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
